BLFS
NASDAQBioLife Solutions Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
News · 26 weeks50-25%
2026-03-012026-08-23
Mix2390d
- Insider12(52%)
- SEC Filings8(35%)
- Earnings2(9%)
- Analyst1(4%)
Latest news
25 items- ANALYSTBioLife Solutions downgraded by The Benchmark CompanyThe Benchmark Company downgraded BioLife Solutions from Buy to Hold
- SECSEC Form 10-Q filed by BioLife Solutions Inc.10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
- SECBioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
- PRBioLife Solutions Reports Second Quarter 2026 Financial ResultsTotal revenue of $28.5 million, up 21% over Q2 2025GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65%GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenueRepligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026BOTHELL, Wash., Aug. 6, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three and six months ended June 30, 2026.
- SECSEC Form 425 filed by BioLife Solutions Inc.425 - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
- SECBioLife Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
- SECSEC Form 425 filed by BioLife Solutions Inc.425 - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
- SECBioLife Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
- SECSEC Form 425 filed by BioLife Solutions Inc.425 - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
- PRRepligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation MediaFast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to receive cash and Repligen common stock at a value of $31.00 per share, representing a total enterprise value of approximately $1.5 billion Compelling financially, the transaction is expected to be accretive to Repligen’s top-line growth, adjusted margins, and adjusted earnings per share by at least 5 cents in year one and at least 25 cents in year two Repligen reports preliminary second quarter reported revenue growth of approximately 12% or 13% organic; BioLife reports preli
- INSIDERChief Technology Officer Werner Sean covered exercise/tax liability with 275 shares, decreasing direct ownership by 0.57% to 47,556 units (SEC Form 4) to satisfy withholding tax4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERChief Financial Officer Wichterman Troy covered exercise/tax liability with 844 shares, decreasing direct ownership by 0.39% to 213,249 units (SEC Form 4) (withholding obligation)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDEREVP & Chief Scientific Officer Mathew Aby J. covered exercise/tax liability with 516 shares, decreasing direct ownership by 0.13% to 388,460 units (SEC Form 4) (for tax liability)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERChief Marketing Officer Berard Todd covered exercise/tax liability with 293 shares, decreasing direct ownership by 0.18% to 162,649 units (SEC Form 4) to cover taxes4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERChief Marketing Officer Berard Todd covered exercise/tax liability with 470 shares, decreasing direct ownership by 0.29% to 162,942 units (SEC Form 4) (tax liability)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERChief Technology Officer Werner Sean covered exercise/tax liability with 420 shares, decreasing direct ownership by 0.87% to 47,831 units (SEC Form 4) (withholding tax)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERChief Financial Officer Wichterman Troy covered exercise/tax liability with 937 shares, decreasing direct ownership by 0.44% to 214,093 units (SEC Form 4) to cover taxes4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDEREVP & Chief Scientific Officer Mathew Aby J. covered exercise/tax liability with 564 shares, decreasing direct ownership by 0.14% to 388,976 units (SEC Form 4) to cover taxes4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERPresident and CEO De Greef Roderick covered exercise/tax liability with 2,775 shares, decreasing direct ownership by 0.38% to 730,971 units (SEC Form 4) to satisfy withholding tax4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERChief Financial Officer Wichterman Troy covered exercise/tax liability with 1,026 shares, decreasing direct ownership by 0.47% to 215,030 units (SEC Form 4) (withholding obligation)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERChief Marketing Officer Berard Todd covered exercise/tax liability with 356 shares, decreasing direct ownership by 0.22% to 163,412 units (SEC Form 4) (tax withholding)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDEREVP & Chief Scientific Officer Mathew Aby J. covered exercise/tax liability with 627 shares, decreasing direct ownership by 0.16% to 389,540 units (SEC Form 4) (for withholding tax)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- SECBioLife Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
- INSIDERLarge owner Casdin Partners Master Fund, L.P. sold $28,125,000 worth of shares (1,200,000 units at $23.44) (SEC Form 4)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- SECSEC Form 10-Q filed by BioLife Solutions Inc.10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
BLFS FAQ
6 questionsWhat does BioLife Solutions Inc. do?
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing...Where does BLFS stock trade?
BioLife Solutions Inc. (BLFS) is listed on NASDAQ.What sector and industry is BLFS in?
BioLife Solutions Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about BLFS?
BioLife Solutions Inc. has had 8 recent analyst actions on file. The most recent action was from The Benchmark Company: Hold on 2026-08-10. Recent price targets range from $2200.00 to $3000.00.What companies are similar to BLFS?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare BLFS side-by-side with any of them on Quantisnow.How can I track BLFS on Quantisnow?
Quantisnow aggregates BioLife Solutions Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BLFS to receive live email and push alerts on every new disclosure.